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ABSTRACT
Background: Little is known about the late clinical outcomes 
of patients undergoing saphenous vein graft percutaneous 
coronary intervention (SVG-PCI), and there are controversies 
regarding the role of lesion location (aorto-ostial or graft body). 
Methods: Single-center registry including patients undergoing 
SVG-PCI between 2006 and 2011. Aorto-ostial lesion was 
defined as a lesion within the first 8 mm of the graft; graft 
body lesion was defined as a lesion located in the remaining 
portions of the graft. Interventions approaching only the distal 
anastomosis or the native coronary bed were excluded. We 
evaluated the rates of major adverse cardiac events (MACE), 
death, myocardial infarction (MI), and target vessel revascu-
larization (TVR) between the groups. Results: One hundred 
and ninety-five patients were evaluated, 69 in the Aorto-Ostial 
Group and 126 in the Graft Body Group. Mean age was 69.6 
± 10.2 years, 41% were diabetic, 65.1% had acute coronary 
syndromes and most of them were treated with bare metal 
stents (82.5%). There was no statistical difference between 
groups for most of the characteristics evaluated. In the late 
follow-up, the TVR rate (50.8% vs. 22%; P = 0.03) was greater 
in the Aorto-Ostial Group. The MACE rate (67.7% vs. 63.3%; 
P = 0.33), death (31.7% vs. 35.6%; P = 0.95) and MI (55% 
vs. 42%; P = 0.64) were similar between the two groups. 
Conclusions: This population included a high-risk subgroup, 
1 Resident Physician in the Department of Interventional Cardio-
logy of the Heart Institute of the Hospital das Clínicas da Facul-
dade de Medicina da Universidade de São Paulo. São Paulo, SP, 
Brazil.
2 Resident Physician in the Department of Interventional Cardio-
logy of the Heart Institute of the Hospital das Clínicas da Facul-
dade de Medicina da Universidade de São Paulo. São Paulo, SP, 
Brazil.
3 Resident Physician in the Department of Interventional Cardiology 
of the Heart Institute of the Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo. São Paulo, SP, Brazil.
4 Graduate student (PhD) at Universidade Laval. Quebec, Canadá.
5 Interventional cardiologist in the Department of Interventional 
Cardiology, Heart Institute of the Hospital das Clínicas da Facul-
dade de Medicina da Universidade de São Paulo. São Paulo, SP, 
Brazil.
6 Interventional cardiologist in the Department of Interventional 
Cardiology, Heart Institute of the Hospital das Clínicas da Facul-
dade de Medicina da Universidade de São Paulo. São Paulo, SP, 
Brazil.
7 Full professor. Interventional cardiologist in the Department of 
Interventional Cardiology, Heart Institute of the Hospital das Clíni-
cas da Faculdade de Medicina da Universidade de São Paulo. São 
Paulo, SP, Brazil.
8 Full professor. Interventional cardiologist in the Department of 
Interventional Cardiology, Heart Institute of the Hospital das Clíni-
cas da Faculdade de Medicina da Universidade de São Paulo. São 
Paulo, SP, Brazil.
9 Professor. Director of the Division of Cardiology, Heart Institute of 
the Hospital das Clínicas da Faculdade de Medicina da Universidade 
de São Paulo. São Paulo, SP, Brazil.
10 Full professor. Director of the Department of Interventional Cardiology, 
Heart Institute of the Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo. São Paulo, SP, Brazil.
Correspondence to: Pedro Alves Lemos Neto. Av. Dr. Enéas Carvalho de 
Aguiar, 44 – Jardim Paulista – São Paulo, SP, Brazil – CEP 05403-000
E-mail: pedro.lemos@incor.usp.br
Received on: 7/1/2013 • Accepted on: 8/31/ 2013
Original Article
RESUMO
Influência da Localização das Lesões nos Desfechos 
Clínicos Tardios após Intervenção Coronária 
Percutânea em Enxertos de Veia Safena
Introdução: A evolução tardia de pacientes submetidos à 
intervenção coronária percutânea em enxertos de veia safena 
(ICP-Saf) é pouco discutida na literatura, havendo, inclusive, 
controvérsias sobre a influência da localização da estenose (em 
posição aorto-ostial ou no corpo do enxerto). Métodos: Registro 
unicêntrico, que incluiu pacientes submetidos à ICP-Saf, entre 
os anos de 2006 e 2011. A lesão aorto-ostial foi definida como 
aquela localizada nos primeiros 8 mm do enxerto; as lesões 
de corpo foram as localizadas nas porções remanescentes. 
Foram excluídas as intervenções que abordaram somente a 
anastomose distal ou o leito coronário nativo. Foram avaliadas 
as taxas de eventos cardíacos adversos maiores (ECAM), óbito, 
infarto agudo do miocárdio (IAM) ou revascularização do 
vaso-alvo (RVA) entre os grupos. Resultados: Foram avaliados 
195 pacientes, sendo 69 no Grupo Óstio e 126 no Grupo 
Corpo. A média de idade da população total foi de 69,6 ± 
10,2 anos, 41% dela era diabética, e 65,1% apresentaram 
síndromes coronárias agudas, sendo a maioria tratada com 
stents convencionais (82,5%). Não houve diferença entre os 
grupos na maioria das características estudadas. No seguimento 
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with high late mortality rates, regardless of the location of 
the lesion in the graft. In patients treated predominantly by 
baremetal stents, aorto-ostial lesions had a higher reinterven-
tion rate when compared to graft body lesions.
 
 
 
 
DESCRIPTORS: Saphenous vein. Percutaneous coronary inter-
vention. Stents. Coronary disease.
lesion located in the first 8 mm of the graft, and the 
body group included patients with localized lesions in 
the remaining portions of the graft. Interventions that 
addressed only the anastomosis or the native coronary 
bed after anastomosis were discarded. With this criterion 
in mind, there was absolutely no restriction for inclusion 
regarding clinical status at admission, age, comorbidities, 
angiographic characteristics, or ventricular function.
Procedure
The platelet anti-aggregation consisted of the admi-
nistration of a loading dose of clopidogrel 300-600 mg 
(with recommendation for 600 mg if the time between 
the administration of the drug and the intervention was 
six hours), followed by 75 mg/day for one month in 
the case of conventional stents and for at least one 
year in the case of drug-eluting stents (DES). Further-
more, patients were instructed to use acetylsalicylic 
acid (100  mg/day) indefinitely. In patients with acute 
coronary syndrome without ST-segment elevation, 
antiplatelet therapy was initiated with acetylsalicylic 
acid and glycoprotein IIb/IIIa inhibitor (tirofiban), with 
replacement of this agent by clopidogrel after PCI. After 
obtaining a vascular access (> 6F) and introducing the 
catheter, unfractionated heparin 70 to 100 IU/kg was 
administered. The stent was implanted according to 
the technique currently established, i.e., direct stent 
introduction, whenever possible. When necessary, 
pre-dilation was performed with short low-pressure 
balloons. The stent was implanted in order to ensure 
full coverage of the lesion and, when necessary, more 
than one stent was used with overlapping of its edges. 
Post-dilation, when indicated, was performed with less 
lengthy balloons compared to the stent, taking care not 
to exceed its borders, thus avoiding lesions to adjacent 
segments not covered by the stent. The use of a distal 
protection filter and of glycoprotein IIb/IIIa inhibitors 
and the selection of the type of stent were left to the 
surgeon’s discretion.
Data collection and analysis
In-hospital progression data were collected by trained 
physicians during the index hospitalization, according 
tardio, a taxa de RVA (50,8% vs. 22%; P = 0,03) foi maior no 
Grupo Óstio. As taxas de ECAM (67,7% vs. 63,3%; P = 0,33), 
morte (31,7% vs. 35,6%; P = 0,95) e IAM (55% vs. 42%; 
P = 0,64) foram semelhantes entre os grupos. Conclusões: Essa 
população compôs um subgrupo de risco elevado, com alta 
mortalidade tardia, independentemente da localização da lesão 
no enxerto. Em pacientes tratados predominantemente com 
stents não farmacológicos, lesões aorto-ostiais apresentaram 
maior taxa de reintervenção em relação às lesões de corpo.
DESCRITORES: Veia safena. Intervenção coronária percutânea. 
Stents. Doença das coronárias.
P ercutaneous coronary interventions in saphenous vein grafts (PCI-Saph) usually occur in a complex scenario. On one side, there’s the patient with 
chronic coronary artery disease, history of CABG, with 
or without previous percutaneous interventions, besides 
multiple comorbidities; on the other, there are the 
peculiarities inherent to the percutaneous procedure 
itself. This intervention can result in distal embolization 
of atherothrombotic debris, often resulting in elevated 
markers of myocardial necrosis and/or in reduced an-
tegrade flow (no-reflow phenomenon).1,2
The lesions may be located on the aorto-ostial 
portion or in the body of the graft. The aorto-ostial 
lesions have a high rate of restenosis compared to 
non-aorto-ostial lesions, due to the greater likelihood 
of suboptimal angiographic results, resulting in greater 
resistance of the lesions to dilation.3-7 Conversely, some 
trials have shown that lesions of the graft body are as-
sociated with post-procedural complications and with 
early worse clinical outcome.8-11 Thus, there is contro-
versy regarding the location of the lesions in the graft 
influencing late clinical outcomes.
This study aimed to characterize, from the evolu-
tionary point of view, the PCI-Saph in a representative 
sample of Brazilian reality, and to assess whether the 
lesion location influences clinical outcomes in a very 
late follow-up.
METHODS
Study population
The study population consisted of patients already 
treated with coronary artery bypass graft (CABG) surgery 
who required PCI-Saph. Patients consecutively treated 
between January of 2006 and March of 2011 in the 
Department of Interventional Cardiology, Instituto do 
Coração, Hospital das Clinicas, Faculdade de Medicina, 
Universidade of São Paulo (Incor-HCFMUSP), São Paulo, 
SP, Brazil, were included in the present study.
The patients were divided into two groups accor-
ding to lesion location: aorto-ostial or body graft. 
The ostium group included patients with at least one 
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to the completion of previously standardized forms. The 
collection included clinical and procedural characteris-
tics, laboratory test results, and clinical evolution until 
discharge. The collection of information about the late 
evolution was performed by outpatient follow-up, review 
of hospital records, or telephone contact.
Objectives and definitions
The primary outcome evaluated was the occurrence 
of major adverse cardiac events (MACE), comprising 
death, acute myocardial infarction (AMI), and target ves-
sel revascularization (TVR). As secondary outcomes, the 
rates of death, AMI, and TVR were analyzed separately. 
The primary objective of the study was to compare the 
occurrence of the primary outcome and of secondary 
outcomes between the Ostium and Body groups.
Periprocedural AMI was defined as the emergence 
of new Q waves in two contiguous leads of the elec-
trocardiogram and/or elevation of creatine kinase MB 
fraction (CK-MB) or a level of troponin I greater than 
three times the upper limit of normal. Markers of myo-
cardial necrosis were requested at least twice in the 
first 24 hours post-PCI.
The diagnosis of stable angina was established 
using the Canadian Cardiovascular Society criteria.12 
It was strongly recommended, but not mandatory, 
that non-invasive tests for ischemia in patients with 
atypical symptoms were performed. The diagnosis of 
AMI with ST-segment elevation was performed in the 
occurrence of persistent ST elevation >  1  mm in two 
contiguous leads, or of a new left branch block in the 
electrocardiogram. Acute coronary syndrome with non-
ST-segment elevation was diagnosed by the presence 
of clinical symptoms suggestive of ischemia associated 
with electrocardiographic alterations compatible with 
ischemia (inverted T wave or ST-segment depression) 
and/or troponin elevation above the normal limit. 
TVR was defined as a new surgical or percutaneous 
intervention in lesions > 50 % in the treated graft, or 
new interventions in the correspondent native coronary 
territory. TVR was conducted only in the presence of 
symptoms and/or signs of ischemia. Angiographic suc-
cess was defined as a reduction of target lesion  30%, 
with maintenance or restoration of a normal antegrade 
flow (Thrombolysis in Myocardial Infarction [TIMI] 3).
Statistical analysis
Qualitative variables were expressed as numbers 
and percentages, and quantitative variables as means 
and standard deviations. The comparison of numeric 
variables was performed through the Mann Whitney 
test, or Pearson’s test, when appropriate. The chi-squared 
test or Fisher’s exact test was used to compare qualita-
tive variables. Survival free of MACE, death, AMI, and 
TVR were estimated using the Kaplan-Meier method. 
The groups were compared using the log-rank test. The 
differences were considered statistically significant when 
P 0.05, and all P-values reported were two-tailed. Data 
were analysed using SPSS, version 12.0 (SPSS Inc. – 
Chicago, USA) software.
RESULTS
Baseline procedural characteristics
195 patients were included, with mean age of 69.6 
± 10.2 years; 73% were male, 41% were diabetics, 
and 65% had acute coronary syndrome on admission. 
Most were treated with bare-metal stents (82.5%). The 
Ostium and Body groups had similar clinical charac-
teristics, except for a higher prevalence of peripheral 
arterial disease in the second group (1.4% vs. 11.1%. 
P = 0.02) (Figure 1). The baseline clinical characteristics 
are shown in Table 1.
The angiographic and procedural characteristics 
are presented in Table 2. The most frequently treated 
territory was supplied by the left circumflex artery 
and its marginal branches (approximately 40%). In the 
index procedure, 1.19 ± 0.52 stents were implanted, 
TABLE 1 
Baseline clinical characteristics
Ostium  
(n = 69)
Body  
(n = 126) P
Age, years 68 ± 11 69 ± 9 0.14
Male gender, n (%) 50 (72.5) 93 (73.8) 0.86
Diabetes mellitus, n (%) 27 (39.1) 53 (42.1) 0.76
Hypertension, n (%) 62 (89.9) 116 (92.1) 0.60
Dyslipidaemia, n (%) 64 (92.8) 123 (97.6) 0.13
Smoking, n (%) 36 (52.2) 66 (52.4) > 0.99
Family history of CAD, 
n (%) 
25 (36.2) 54 (42.9) 0.44
Prior stroke, n (%) 2 (2.9) 7 (5.6) 0.49
Peripheral arterial 
insufficiency, n (%)
1 (1.4) 14 (11.1) 0.02
Heart failure, n (%) 24 (34.8) 51 (40.5) 0.44
CRF, n (%) 23 (33.3) 42 (33.3) > 0.99
Clinical picture 0.73
Stable angina/silent 
ischemia 
22 (31.8) 44 (34.9)
NSTE-ACS 40 (57.9) 66 (52.3)
STE-ACS 7 (10.1) 16 (12.6)
CAD = coronary artery disease; CRF = chronic renal failure 
(creatinine clearance 60 mL/min); NSTE-ACS = non-ST-segment 
elevation acute coronary syndrome; STE-ACS = ST-segment 
elevation acute coronary syndrome.
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on average, per vessel; in most of these patients, bare-
metal stents were used (82.5% in the Ostium group vs. 
81.6% in the Body group; P = 0.84).
In relation to periprocedural medications, there 
was also no significant difference between groups. A 
trend towards a lower rate of angiographic success in 
Ostium group (92.7% vs. 97.6%; P = 0.10) was noted. 
The mean diameter and length of the stents were, 
respectively, 3.56 ± 0.6 mm vs. 3.52 ± 0.6 mm (P = 
0.82) and 18.7 ± 5.6 mm vs. 20.3 ± 6.6 mm (P = 0.71). 
The mean peak CK-MB in the first 48 hours after the 
procedure was 40.9 ± 88 mg/dL vs. 49.2 ± 101 mg/
dL (P = 0.35). Distal embolic protection (Filter Wire®) 
devices were rarely used: one in the Ostium group and 
eight in the Body group (P = 0.19). The occurrence of 
no-reflow phenomenon was similar between groups 
(8.6% vs. 7.9%; P  =  0.85).
The median follow-up time was 31.7 ± 22.9 
months. There was no significant difference between 
groups regarding mortality (31.7% vs. 35.6%; P = 0.95), 
occurrence of MACE (67.7% vs. 63.3%; P = 0.31), or 
occurrence of AMI (42% vs. 55%; P = 0.64). However, 
in the Ostium group, a higher incidence of TVR (50.8% 
vs. 22%; P = 0.03) was observed.
DISCUSSION
The main finding of the present study was the high 
occurrence of MACE at late follow-up, regardless of the 
location of the lesion, with greater occurrence of TVR 
in ostial lesions. These findings should be interpreted 
in the context of this population, which is repre-
sentative of the Brazilian reality and of the scenario 
often encountered in PCI-Saph.13-15 This is a high risk 
population for new cardiovascular events; over 60% of 
patients had acute coronary syndrome, approximately 
40% were diabetics and over one-third of patients had 
heart failure and chronic renal failure. Furthermore, the 
rate of use of distal embolic protection devices was 
low, and conventional stents were used in over 80% of 
patients, because most of these procedures are linked 
to the Brazilian Unified Health System (Sistema Único 
de Saúde - SUS).
Some studies have demonstrated that lesions of the 
saphenous graft body are more strongly associated with 
post-procedural complications and with a worse early 
clinical outcome, due to distal embolization of athero-
thrombotic debris into the native coronary circulation, 
often resulting in an increase of markers of myocardial 
necrosis or in a reduction of the antegrade flow (no-
reflow phenomenon).1 Analyzing only the subgroup of 
patients with stable coronary artery disease (n = 66), 
a higher, although not statistically significant incidence 
of periprocedural myocardial infarction was noted in 
Body group vs. the Ostium group (18.1% vs. 27.2% 
P = 0.42), possibly due to the small number of patients 
with stable coronary disease.
Hong et al.8 published a study that evaluated, 
through intracoronary ultrasound, the characteristics 
of aorto-ostial and body of saphenous graft lesions, in 
addition to clinical evolution, showing a higher incidence 
of death and myocardial infarction for the body lesions 
and similar rates of TVR between groups. Unlike the 
present study, in the trial by Hong et al., approximately 
80% of patients were approached with DES, and only 
10% to 15% of these patients had a diagnosis of AMI, 
indicating a low-risk population.
Toutouzas et al.5 demonstrated that aorto-ostial 
lesions of native coronary artery or of saphenous grafts 
TABLE 2 
Angiographic and procedural characteristics
Ostium  
(n = 69)
Body  
(n = 126) P
Treated vessels, n (%) 0.12
LAD 25 (33.7) 33 (25.3)
LCx 31 (41.9) 52 (40.0)
RC 18 (24.3) 45 (34.6)
Periprocedural medications, 
n (%) 
ASA 66 (97.1) 124 (98.4) 0.61
Clopidogrel 43 (63.2) 87 (69) 0.42
GP IIb/IIIa inhibitor 23 (33.8) 58 (46) 0.12
LMWH 26 (38.2) 44 (34.9) 0.64
UFH 67 (98.5) 125 (99.2) > 0.99
Stents used, n (%) 0.84
DES 16 (17.5) 30 (18.4)
Conventional 75 (82.5) 133 (81.6)
Number of stents per 
patient 
1.3 ± 0.5 1.3 ± 0.6 0.10
Contrast volume, mL 249 ± 92 243 ± 91 0.69
Stent diameter, mm 3.56 ± 0.6 3.52 ± 0.6 0.82
Stent length, mm 18.7± 5.6 20.3 ± 6.6 0.71
Protective embolic distal 
devices, n (%) 
1 (1.4) 8 (6.3) 0.19
No reflow, n (%) 6 (8.6) 10 (7.9) 0.85
CK-MB, mean (mg/dL) 
Basal 11.5 ± 31 14.9 ± 52 0.40
Peak at 48 hours post-PCI 40.9 ± 88 49.2 ± 101 0.35
Angiographic success, n (%) 64 (92.7) 123 (97.6) 0.10
LAD = left anterior descending; LCx = left circumflex artery; 
RC = right coronary artery; ASA = acetylsalicylic acid; GP = 
glycoprotein; LMWH = low molecular weight heparin; UFH 
= unfractionated heparin; DES = drug eluting stent; CK-MB 
= creatine kinase MB fraction; PCI = percutaneous coronary 
intervention.
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in the aorto-ostial or proximal portion (62% vs. 42%, 
respectively). Ellis et al.17 demonstrated that the disease 
in saphenous vein grafts has a rapidly progressive 
character, resulting, in large part, from the evolution of 
the disease in untreated segments, and that the occur-
rence of TVR following the intervention in saphenous 
grafts after the first year may occur more commonly 
in untreated locations, rather than in the target lesion. 
Restenosis and progression of atherosclerotic disease are 
the causes of long-term failure of PCI-Saph,17,18 which 
could explain the unfavorable evolution in both groups 
and the higher incidence of TVR in the Ostium group.
Limitations of the study
The main limitations of this study were its retros-
pective and observational character, with limitations 
inherent to this type of research; the small number of 
are related to the high incidence of restenosis, showing 
no benefit of the conventional stent coated with po-
litetrafluoroethylene (PTFE). Traditionally, the presence 
of an aorto-ostial stenosis puts the interventionist into 
a difficult situation, since these lesions are most often 
associated with suboptimal angiographic results due to 
the greater resistance of the lesion to dilation, the pre-
sence of calcification, and the increased elastic recoil 
of the vessel.9 Iakovou et al.4 published clinical and 
angiographic results demonstrating that, when com-
pared with conventional stents in aorto-ostial lesions, 
the implantation of DES is safe and effective, with a 
reduction in restenosis rates.
Caños et al.16 published data suggesting that grafts 
with early failure ( one year after surgery) had more 
aggressive and diffuse degenerative/atherosclerotic dise- 
ase, and the culprit lesions were located predominantly 
Figure 1 – Incidence of death, myocardial infarction, and target vessel revascularization combined (MACE) or isolated during follow-up. MACE = 
major adverse cardiac events; AMI = acute myocardial infarction; TVR = target vessel revascularisation.
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patients treated with DES; and the low rate of use of 
distal embolic protection devices.
Nevertheless, it was possible demonstrate the diffi- 
culties inherent to PCI-Saph, especially regarding the 
high incidence of adverse events at the late follow-up 
of this Brazilian population in clinical practice. TVR 
rates in aorto-ostial lesions showed significant diffe-
rences when compared to lesions in the body of the 
saphenous graft. Specific studies are needed to clarify 
the best conduct and follow-up strategy for patients 
undergoing PCI-Saph, particularly in aorto-ostial 
lesions.
CONCLUSIONS
Patients with previous CABG requiring percutaneous 
coronary interventions in saphenous vein grafts com-
prise a subgroup of high risk, with high late mortality, 
regardless of lesion location in the graft. In patients 
predominantly treated with conventional stents (i.e., 
non-DES), aorto-ostial lesions had higher re-intervention 
rates versus lesions in the body of saphenous grafts.
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